Skip to main content

Ultrahigh Field Metabolic MRI: Current Status, Clinical Applications and Future Perspectives.

43kviews
Editorial24 January 2023
Editorial: Ultrahigh field metabolic MRI: Current status, clinical applications, and future perspectives

Nevertheless, technical advances at lower field strengths -like acceleration techniques or new AI applications that can synthesize equally high-resolution, high contrast-to-noise ratio (CNR) images from lower field data -have started to make clinically more accepted lower field strengths serious competitors regarding image detail and speed. However, another advantage of UHF MRI that cannot be readily achieved at lower field strengths is its increased spectral resolution and consequent increased sensitivity to (macro)molecules and nuclei other than protons (x-nuclei) that could be of clinical interest. For instance, magnetization transfer techniques at UHF provide more detailed information on different metabolites, which can be utilized to for instance probe the structure of myelin, an essential element in the transport of nerve impulses. Another example is MR spectroscopy, which seems to have never really achieved its full potential in the clinic, not in the least due to overlapping metabolites hampering true tissue probing. UHF MRI therefore could give us access not only to anatomy with a precision that is not readily accessible on standard clinical devices, but also to metabolism, ionic homeostasis, and energetic processes in vivo within the human body with an unmatched quality. In addition, its non-invasive character allows repeated measurements and thus the generation of kinetic profiles, opening up the possibility of producing biometabolic models that no longer systematically use animal models. Thus, UHF imaging allows to move from an anatomical representation to a dynamic metabolic representation.The articles in this Research Topic provide just a glimpse of the full potential of UHF MRI to visualize metabolites and metabolic pathways, using either proton or x-nuclei imaging. Although the latter necessitates new hardware to be developed, the UHF community has ample experience in this field, as shown in the article by Forner et al. who used specially designed coils for phosphorus spectroscopy exploration of tongue tumors. Phosphorus imaging is also used by Korzovski et al., who show the improvement of regional glioma mapping using 31 P MRS. High spatial resolution sampling allows a better characterization of intra-and peritumoral tissue heterogeneity. This possibility to obtain, without sampling or biopsy, metabolic or genetic information predictive of clinical outcome defines a personalized follow-up in line with 5Ps medicine. Jumping from one x-nucleus to another, Stobbe et al. shows the possibility of identifying and quantifying an alteration of the intra-extracellular sodium compartmentalization in relation to Multiple Sclerosis. Grimaldi et al. even identified new biomarkers using sodium MRI and thus envisaged new pathophysiological approaches in idiopathic Parkinson's disease, by showing an abnormal sodium accumulation within dopaminergic neurons.It is not only x-nuclei imaging where UHF MRI excels compared to lower field strengths. Quantification -instead of using ratios -of neurotransmitters is now a possibility, for instance glutamate which is studied in two studies presented in this Research Topic. O'Grady et al. uses a CEST sequence to measure glutamate in MS patients, finding a correlation between glutamate in certain regions and disability and cognitive function, while Park et al. developed a protocol for glutamate and GABA measurements that can be used for probing the changes of these neurotransmitters under different conditions, like hyperglycemia. Finally, Shams et al. shows the potential of UHF metabolic MRI to extract genomic information in vivo, by detecting 2OH Glutarate (2HG), a metabolic correlate of the IDH mutation quantified in a much more reliable manner than at 3T. By in vivo functional and metabolic sampling of the brain, UHF paves the way to in vivo characterization of genomic mutations by means of their metabolic counterparts. Combining this with AI-driven quantitative analysis of the data could ultimately lead to the development of a 'digital twin': rebuilding a lesion within the organ, allowing virtual biopsy as well as therapeutic simulation (e.g., neurosurgical procedures) and treatment monitoring, all in a noninvasive way.

1,546 views

1 citations

Relaxation-Compensated Chemical Exchange Saturation Transfer MRI in the Brain at 7T: Application in Relapsing-Remitting Multiple Sclerosis
ORIGINAL RESEARCH
25 February 2022
Relaxation-Compensated Chemical Exchange Saturation Transfer MRI in the Brain at 7T: Application in Relapsing-Remitting Multiple Sclerosis
Kristin P. O'Grady, 15 more and Seth A. Smith
Chemical exchange saturation transfer (CEST) magnetic resonance imaging (MRI) can probe tissue biochemistry in vivo with high resolution and sensitivity without requiring exogenous contrast agents. Applying CEST MRI at ultrahigh field provides advantages of increasing spectral resolution and improving sensitivity to metabolites with faster proton exchange rates such as glutamate, a critical neurotransmitter in the brain. Prior magnetic resonance spectroscopy and CEST MRI studies have revealed altered regulation of glutamate in patients with multiple sclerosis (MS). While CEST imaging facilitates new strategies for investigating the pathology underlying this complex and heterogeneous neurological disease, CEST signals are contaminated or diluted by concurrent effects (e.g., semi-solid magnetization transfer (MT) and direct water saturation) and are scaled by the T1 relaxation time of the free water pool which may also be altered in the context of disease. In this study of 20 relapsing-remitting MS patients and age- and sex-matched healthy volunteers, glutamate-weighted CEST data were acquired at 7.0 T. A Lorentzian fitting procedure was used to remove the asymmetric MT contribution from CEST z-spectra, and the apparent exchange-dependent relaxation (AREX) correction was applied using an R1 map derived from an inversion recovery sequence to further isolate glutamate-weighted CEST signals from concurrent effects. Associations between AREX and cognitive function were examined using the Minimal Assessment of Cognitive Function in MS battery. After isolating CEST effects from MT, direct water saturation, and T1 effects, glutamate-weighted AREX contrast remained higher in gray matter than in white matter, though the difference between these tissues decreased. Glutamate-weighted AREX in normal-appearing gray and white matter in MS patients did not differ from healthy gray and white matter but was significantly elevated in white matter lesions. AREX in some cortical regions and in white matter lesions correlated with disability and measures of cognitive function in MS patients. However, further studies with larger sample sizes are needed to confirm these relationships due to potential confounding effects. The application of MT and AREX corrections in this study demonstrates the importance of isolating CEST signals for more specific characterization of the contribution of metabolic changes to tissue pathology and symptoms in MS.

5,514 views

20 citations

Mapping an Extended Metabolic Profile of Gliomas Using High-Resolution 31P MRSI at 7T
ORIGINAL RESEARCH
23 December 2021
Mapping an Extended Metabolic Profile of Gliomas Using High-Resolution 31P MRSI at 7T
Andreas Korzowski, 7 more and Daniel Paech
Phosphorus magnetic resonance spectroscopic imaging (31P MRSI) is of particular interest for investigations of patients with brain tumors as it enables to non-invasively assess altered energy and phospholipid metabolism in vivo. However, the limited sensitivity of 31P MRSI hampers its broader application at clinical field strengths. This study aimed to identify the additional value of 31P MRSI in patients with glioma at ultra-high B0 = 7 T, where the increase in signal-to-noise ratio may foster its applicability for clinical research. High-quality, 3D 31P MRSI datasets with an effective voxel size of 5.7 ml were acquired from the brains of 7 patients with newly diagnosed glioma. An optimized quantification model was implemented to reliably extract an extended metabolic profile, including low-concentrated metabolites such as extracellular inorganic phosphate, nicotinamide adenine dinucleotide (NAD(H)), and uridine diphosphoglucose (UDPG), which may act as novel tumor markers; a background signal was extracted as well, which affected measures of phosphomonoesters beneficially. Application of this model to the MRSI datasets yielded high-resolution maps of 12 different 31P metabolites, showing clear metabolic differences between white matter (WM) and grey matter, and between healthy and tumor tissues. Moreover, differences between tumor compartments in patients with high-grade glioma (HGG), i.e. gadolinium contrast-enhancing/necrotic regions (C+N) and peritumoral edema, could also be suggested from these maps. In the group of patients with HGG, the most significant changes in metabolite intensities were observed in C+N compared to WM, i.e. for phosphocholine +340%, UDPG +54%, glycerophosphoethanolamine -45%, and adenosine-5’-triphosphate -29%. Furthermore, a prominent signal from mobile phospholipids appeared in C+N. In the group of patients with low-grade glioma, only the NAD(H) intensity changed significantly by -28% in the tumor compared to WM. Besides the potential of 31P MRSI at 7T to provide novel insights into the biochemistry of gliomas in vivo, the attainable spatial resolutions improve the interpretability of 31P metabolite intensities obtained from malignant tissues, particularly when only subtle differences compared to healthy tissues are expected. In conclusion, this pilot study demonstrates that 31P MRSI at 7T has potential value for the clinical research of glioma.

4,881 views

17 citations

Increased Sodium Concentration in Substantia Nigra in Early Parkinson's Disease: A Preliminary Study With Ultra-High Field (7T) MRI
Pathophysiology of idiopathic Parkinson’s disease (iPD) is complex and still misunderstood. At a time when treatments with disease-modifying potential are being developed, identification of early markers of neurodegeneration is essential. Intracerebral sodium accumulation could be one of them. Indeed, it may be in relation to the mitochondrial dysfunction that early exists in iPD. For the first time, we used brain sodium (23Na) MRI to explore sodium concentration changes that have already been reported to be related to neurodegeneration in other diseases. We prospectively included 10 iPD patients (mean age 52.2 ± 5.9 years-old) with motor symptoms that started less than 36 months before inclusion and 12 healthy subjects (mean age 53 ± 6.4 years-old). Patients were scanned in OFF medication state by using proton (1H) and 23Na MRI at 7T. We then extracted quantitative Total Sodium Concentration (TSC) from five regions of interest known to be early impaired in iPD (substantia nigra (SN), putamen, caudate nucleus, pallidum, thalamus) and in one region supposed to be relatively spared in the first stages of the disease (cortical grey matter (neocortex)). Potential atrophy in these structures was also investigated with 1H MRI. Relative to healthy subjects, iPD patients showed higher TSC in the SN (43.73 ± 4.64 vs 37.72 ± 5.62, p = 0.006 after Bonferroni correction). A trend of increase in sodium concentrations was found within the pallidum (45.80 ± 4.19 vs 41.07 ± 4.94, p= 0.017), putamen (48.65 ± 4.58 vs 43.66 ± 5.04, p = 0.041) and the cortical grey matter (56.34 ± 3.92 vs 50.81 ± 5.50, p = 0.021). No significant brain atrophy was found in patients compared to controls. Thus, alteration of sodium homeostasis in the SN in the absence of atrophy could be considered as a potential early marker of cellular dysfunction in iPD.

4,097 views

20 citations

Comparison of 2-Hydroxyglutarate Detection With sLASER and MEGA-sLASER at 7T
The onco-metabolite 2-hydroxyglutarate (2HG), a biomarker of IDH-mutant gliomas, can be detected with 1H MR spectroscopy (1H-MRS). Recent studies showed measurements of 2HG at 7T with substantial gain in signal to noise ratio (SNR) and spectral resolution, offering higher specificity and sensitivity for 2HG detection. In this study, we assessed the sensitivity of semi-localized by adiabatic selective refocusing (sLASER) and J-difference MEsher-GArwood-semi-LASER (MEGA-sLASER) for 2HG detection at 7T. We performed spectral editing at long TE using a TE-optimized sLASER sequence (110ms) and J-difference spectroscopy using MEGA-sLASER (TE=74ms) in phantoms with different 2HG concentrations to assess the sensitivity of 2HG detection. The robustness of the methods against B0 inhomogeneity was investigated. Moreover, the performance of these two techniques was evaluated in four patients with IDH1-mutated glioma. In contrary to MEGA-sLASER, sLASER was able to detect 2HG concentration as low as 0.5 mM. In case of a composite phantom containing 2HG with overlapping metabolites, MEGA-sLASER provided a clean 2HG signal with higher fitting reliability (lower %CRLB). The results demonstrate that sLASER is more robust against field inhomogeneities and experimental or motion-related artifacts which promotes to adopt sLASER in clinical implementations.

5,810 views

17 citations